Saturday, 2 July 2022

Australia's most trusted
source of pharma news

Saturday, 02 July 2022
Listen to this story 

Roche set to conquer top market

Posted 20 June 2022 AM

All new listings considered at the PBAC's May intracycle meeting were recommended, including Roche's yet to be TGA approved eye drug Vabysmo, which is expected to hit blockbuster status.

The PBAC has recommended listing Vabysmo in two indications - neo-vascular (wet) age-related macular degeneration and diabetic macular oedema.

Its decision sets up a battle with the sponsors of current standard-of-care treatments, including Novartis' (Lucentis) and Bayer's (Eylea).

To see the whole article, please login

Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (7)

Sales & Customer Relations (24)

Access & Reimbursement (2)

Clinical & Medical, R&D (16)

Regulatory, Pharmacovigilance & QA (8)

Devices (2)

Other (34)

Email this article to a friend

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.


Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.


Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).


You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.


You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.